Showing results (71-80 of 124) with videos related to
Sort By:
Pageof 13
American Journal of Obstetrics and Gynecology|September 6, 2011
Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibodyJoyce Varughese, Emiliano Cocco, Stefania Bellone, et al.Journal of the American Medical Directors Association|June 1, 2014
Prescription drug use among older adults in Italy: a country-wide perspectiveGraziano Onder, Davide Liborio Vetrano, Antonio Cherubini, et al.Gynecologic Oncology|May 17, 2005
Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridizationAlessandro D Santin, Stefania Bellone, Sue Van Stedum, et al.American Journal of Obstetrics and Gynecology|April 16, 2013
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupiloneDana M Roque, Stefania Bellone, Natalia Buza, et al.Cancer|January 2, 2009
Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancerStefania Bellone, Simone Anfossi, Timothy J O'Brien, et al.Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 4, 2015
An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for ErythropoietinAlessandra Gianoncelli, Sara A Bonini, Michela Bertuzzi, et al.Journal of the National Cancer Institute|January 17, 2003
International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinomaJ Baptist Trimbos, Mahesh Parmar, Ignace Vergote, et al.Cancer|August 24, 2005
Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinomaAlessandro D Santin, Stefania Bellone, Sue Van Stedum, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Overexpression of HER-2/neu in uterine serous papillary cancerAlessandro D Santin, Stefania Bellone, Murat Gokden, et al.Oncology Letters|October 5, 2016
The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell linesElisabetta Bandiera, Paola Todeschini, Chiara Romani, et al.Pageof 13